‘Multiplexing’ has been one of the most prominent buzzwords of 2023 in the advanced therapies space. David McCall, Senior Editor, Cell & Gene Therapy Insights,speaks to Marco Alessandrini, CEO, Antion Biosciences about recent progress with and future targets for tunable multiplex cell engineering platforms.
